Thus, loss of Cyrib in the pancreas accelerates progression to end-point of KRASG12D, p53R172H-driven PDAC in the KPC model, but does not grossly alter levels of cell growth/death or histological appearance of end-point tumours. This evidence concerns the gene CYRIB and neoplasm.